CytomX Therapeutics Revenue 2014-2022 | CTMX

CytomX Therapeutics revenue from 2014 to 2022. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
CytomX Therapeutics Annual Revenue
(Millions of US $)
2021 $70
2020 $100
2019 $57
2018 $60
2017 $72
2016 $15
2015 $8
2014 $5
2013 $1
CytomX Therapeutics Quarterly Revenue
(Millions of US $)
2022-09-30 $17
2022-06-30 $18
2022-03-31 $17
2021-12-31 $20
2021-09-30 $18
2021-06-30 $16
2021-03-31 $16
2020-12-31 $16
2020-09-30 $18
2020-06-30 $17
2020-03-31 $50
2019-12-31 $8
2019-09-30 $11
2019-06-30 $9
2019-03-31 $29
2018-12-31 $11
2018-09-30 $13
2018-06-30 $21
2018-03-31 $14
2017-12-31 $27
2017-09-30 $24
2017-06-30 $9
2017-03-31 $12
2016-12-31 $6
2016-09-30 $3
2016-06-30 $3
2016-03-31 $2
2015-12-31 $2
2015-09-30 $2
2015-06-30 $2
2015-03-31 $2
2014-12-31
2014-09-30 $2
2013-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.171B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $154.721B 9.45
GSK (GSK) United Kingdom $71.915B 9.49
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.215B 19.14
Ginkgo Bioworks Holdings (DNA) United States $4.249B 0.00
Myovant Sciences (MYOV) United Kingdom $2.615B 0.00
Arcus Biosciences (RCUS) United States $1.532B 23.00
Biohaven (BHVN) United States $1.307B 0.00
Emergent Biosolutions (EBS) United States $0.726B 5.71
ADC Therapeutics SA (ADCT) Switzerland $0.376B 0.00
Ambrx Biopharma (AMAM) United States $0.071B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.023B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00